Capsaicin 8% Topical Patch (Qutenza)—A Review of the Evidence

REFERENCES

• Neuroges X. Qutenza (capsaicin) 8% patch [product information]. San Mateo, CA: NeurogesX, Inc; 2009.
   Google Scholar
• Center for Drug Evaluation and Research. Summary Review. Application 22–395. Food and Drug Administration Department of Health and Human Services. Available at: http://www. accessdata.fda.gov/drugsatfda_docs/nda/2009/022395s000Sumr. pdf. Accessed September 29, 2010.
   Google Scholar
• Endo Pharmaceuticals Inc. Lidoderm (lidocaine patch 5%) [product information]. Chadds Ford, PA: Endo Pharmaceuticals Inc.; 2010.
   Google Scholar
• Pfizer Inc. Neurontin (gabapentin) [product information]. New York, NY: Pfizer Inc; 2009.
   Google Scholar
• Pfizer Inc. Lyrica (pregabalin) [product information]. New York, NY: Pfizer Inc; 2009.
   Google Scholar
• Simpson DM, Brown S, Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70:2305–2313.
   PubMed Web of Science ®Google Scholar
• Simpson DM, Estanislao L, Brown SJ, Sampson J. An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy. J Pain Symptom Manage. 2008;35:299–306.
   PubMedGoogle Scholar
• Johnson RW Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines. 2010;9(3 Suppl):21–26.
   PubMed Web of Science ®Google Scholar
• Weaver BA The burden of herpes zoster and postherpetic neuralgia in the United States. J Am Osteopath Assoc. 2007;107(3 Suppl 1):S2–S7.
   Google Scholar
• Harpaz R, Ortega-Sanchez IR, Seward JF Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1–30; quiz CE32–CE34.
   PubMedGoogle Scholar
• Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63:959–965.
   PubMed Web of Science ®Google Scholar
• Thakur R, Kent JL, Dworkin RH Herpes zoster and postherpetic neuralgia. In: Fishman SM, Ballantyne JC, Rathmell JP, eds. Bonica's Management of Pain. 4th ed. Baltimore, MD: Wolters Kluwer; Lippincott Williams & Wilkins; 2010:338–357.
   Google Scholar
• Attal N, Cruccu G, Haanpaa M, EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13:1153–1169.
   PubMed Web of Science ®Google Scholar
• Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med. 2005;2:e164.
   PubMed Web of Science ®Google Scholar
• Backonja M, Wallace MS, Blonsky ER, NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7:1106–1112.
   PubMed Web of Science ®Google Scholar
• Kennedy WR, Vanhove GF, Lu SP, A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain. 2010;11:579–587.
   PubMed Web of Science ®Google Scholar
• Babbar S, Marier JF, Mouksassi MS, Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ther Drug Monit. 2009;31:502–510.
   PubMed Web of Science ®Google Scholar
• Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain. 1999;81:135–145.
   PubMed Web of Science ®Google Scholar
• Reilly CA, Yost GS. Metabolism of capsaicinoids by P450 enzymes: a review of recent findings on reaction mechanisms, bio-activation, and detoxification processes. Drug Metab Rev. 2006;38:685–706.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. Medical Review(s). Application 22–395. Food and Drug Administration, Department of Health and Human Services. Available at: http://www. accessdata.fda.gov/drugsatfda_docs/nda/2009/022395s000Medr. pdf. Accessed September 29, 2010.
   Google Scholar
• Backonja M, Dunteman E, Irving GA, One 60-minute application of a high-concentration capsaicin patch (NGX-4010) significantly reduced pain for up to 3 months in patients with postherpetic neuralgia: results from a randomized, double-blind, controlled Phase 3 study [abstract]. Presented at 60th Annual Meeting of the American Academy of Neurology (AAN); Chicago, IL; April 12–19, 2008.
   Google Scholar
• Backonja M, Dunteman E, Irving GA, One-hour application of NGX-4010, a high-concentration capsaicin patch, in postherpetic neuralgia [abstract]. Presented at 19th Annual Meeting of the American Academy of Pain Management (AAPM); Nashville, TN; September 8–11, 2008.
   Google Scholar
• Irving GA, Blonsky ER, Backonja MM, Lu SP, Vanhove GF, Tobias J. An efficacy and safety analysis of a single one-hour application of NGX-4010 in patients with postherpetic neuralgia: results of a randomized, double-blind, 12-week, controlled study [abstract]. Presented at 12th World Congress on Pain; Glasgow, Scotland; August 17–22, 2008.
   Google Scholar
• Backonja MM, Malan TP, Vanhove GF, Tobias JK. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med. 2010;11:600–608.
   PubMed Web of Science ®Google Scholar
• Webster LR, Malan TP, Tuchman MM, Mollen MD, Tobias JK, Vanhove GF. A Multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. J Pain. Jul 22 2010;11(10):972–982.
   PubMed Web of Science ®Google Scholar
• Simpson DM, Gazda S, Brown S, Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage. 2010;39:1053–1064.
   PubMed Web of Science ®Google Scholar
• Neuroges X. Qutenza (capsaicin) 8% patch [dossier]. San Mateo, CA: NeurogesX, Inc.; 2009.
   Google Scholar